Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.73 |
| ▸ | ITGAV | P06756 | 18/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026489 | 0.97 | ITGB3 (0.71) | ITGB3ITGAVHSD17B10GSK3AGSK3B | |
| SCHEMBL5029944 | 0.84 | ITGB3 (1.00) | ITGB3ITGAV | |
| SCHEMBL5025481 | 0.84 | ITGB3 (1.00) | ITGB3ITGAV | |
| SCHEMBL5026293 | 0.84 | ITGB3 (1.00) | ITGB3ITGAV | |
| SCHEMBL5025476 | 0.83 | ITGB3 (0.88) | ITGB3ITGAV | |
| SCHEMBL6424626 | 0.82 | ITGB3 (0.59) | ITGB3ITGAVHSD17B10 | |
| SCHEMBL5029817 | 0.81 | ITGB3 (0.73) | ITGB3ITGAV | |
| SCHEMBL5025457 | 0.81 | ITGB3 (0.72) | ITGB3ITGAV | |
| SCHEMBL5028367 | 0.80 | ITGB3 (0.79) | ITGB3ITGAV | |
| SCHEMBL5030043 | 0.80 | ITGB3 (0.70) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1286673-B1 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885HSD17B10 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.